Latest News and Press Releases

First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA...

A synthetic recombinant PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases

Both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP

"We feel strongly about undertaking important corporate actions that reflect the true value of our shareholders’ equity."

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a...

Reprogram Biosciences closed its seed financing, bringing total capital raised to $6 million since founding.

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial